Profile data is unavailable for this security.
About the company
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
- Revenue in USD (TTM)1.08m
- Net income in USD-106.31m
- Incorporated2018
- Employees138.00
- LocationPerspective Therapeutics Inc2401 Elliott Avenue, Suite 320SEATTLE 98121United StatesUSA
- Phone+1 (206) 676-0900
- Fax+1 (302) 636-5454
- Websitehttps://www.perspectivetherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organogenesis Holdings Inc | 465.22m | -13.39m | 487.34m | 869.00 | -- | 1.91 | 101.78 | 1.05 | -0.1108 | -0.1108 | 3.62 | 3.04 | 0.9731 | 3.56 | 3.45 | 535,348.70 | 0.2102 | 6.65 | 0.2549 | 8.18 | 74.49 | 75.66 | 0.216 | 6.14 | 2.88 | -- | 0.0085 | 0.00 | 11.29 | 13.06 | -118.95 | -- | 9.98 | -- |
| Neumora Therapeutics Inc | 0.00 | -236.30m | 492.74m | 95.00 | -- | 3.66 | -- | -- | -1.46 | -1.46 | 0.00 | 0.8161 | 0.00 | -- | -- | 0.00 | -89.11 | -55.45 | -99.96 | -58.77 | -- | -- | -- | -- | -- | -- | 0.1289 | -- | -- | -- | -3.33 | -- | -- | -- |
| Lyell Immunopharma Inc | 41.00k | -325.66m | 503.69m | 300.00 | -- | 1.39 | -- | 12,285.22 | -22.26 | -22.26 | 0.0027 | 17.06 | 0.00008 | -- | -- | 136.67 | -63.41 | -28.62 | -67.72 | -30.08 | -- | -- | -794,292.70 | -1,176.84 | -- | -- | 0.00 | -- | -53.08 | -37.83 | -46.18 | -- | 14.67 | -- |
| Lexeo Therapeutics Inc | 0.00 | -104.97m | 513.83m | 72.00 | -- | 3.20 | -- | -- | -2.70 | -2.70 | 0.00 | 2.20 | 0.00 | -- | -- | 0.00 | -66.08 | -- | -76.72 | -- | -- | -- | -- | -- | -- | -- | 0.0084 | -- | -- | -- | -48.11 | -- | -- | -- |
| Alto Neuroscience Inc | 0.00 | -62.26m | 517.25m | 76.00 | -- | 4.05 | -- | -- | -2.31 | -2.31 | 0.00 | 4.11 | 0.00 | -- | -- | 0.00 | -36.77 | -- | -39.46 | -- | -- | -- | -- | -- | -- | -- | 0.1675 | -- | -- | -- | -69.21 | -- | -- | -- |
| Keros Therapeutics Inc | 246.72m | 64.45m | 522.49m | 82.00 | 11.11 | 0.9904 | 7.93 | 2.12 | 1.54 | 1.54 | 6.07 | 17.32 | 0.3732 | -- | 127.17 | 1,459,870.00 | 9.75 | -36.26 | 10.16 | -38.17 | -- | -- | 26.12 | -2,307.89 | -- | -- | 0.00 | -- | 2,250.99 | -18.71 | -22.46 | -- | 48.10 | -- |
| Altimmune Inc | 20.00k | -83.92m | 524.68m | 59.00 | -- | 2.40 | -- | 26,233.81 | -1.07 | -1.07 | 0.0003 | 1.94 | 0.0001 | -- | 0.0314 | 338.98 | -45.82 | -42.36 | -48.64 | -45.46 | -- | -- | -419,575.00 | -3,193.88 | -- | -- | 0.0722 | -- | -95.31 | -67.83 | -7.48 | -- | -- | -- |
| Ginkgo Bioworks Holdings Inc | 180.61m | -339.55m | 531.56m | 834.00 | -- | 0.9372 | -- | 2.94 | -6.22 | -6.22 | 3.31 | 9.85 | 0.1353 | -- | 7.80 | 216,554.00 | -25.43 | -68.97 | -27.83 | -75.53 | 72.71 | 66.73 | -188.00 | -409.12 | -- | -- | 0.00 | -- | -9.71 | 33.18 | 38.73 | -- | 23.00 | -- |
| Gossamer Bio Inc | 44.05m | -156.16m | 539.29m | 144.00 | -- | -- | -- | 12.24 | -0.6872 | -0.6872 | 0.1939 | -0.356 | 0.1574 | -- | 5.57 | 305,909.70 | -55.80 | -51.30 | -69.95 | -58.28 | -- | -- | -354.50 | -822.21 | -- | -15.04 | 1.71 | -- | -- | -- | 68.56 | -- | -- | -- |
| Solid Biosciences Inc | 0.00 | -167.14m | 539.92m | 100.00 | -- | 2.48 | -- | -- | -2.49 | -2.49 | 0.00 | 2.80 | 0.00 | -- | -- | 0.00 | -68.82 | -47.92 | -78.37 | -53.98 | -- | -- | -- | -2,151.47 | -- | -- | 0.0013 | -- | -- | -- | -29.87 | -- | -31.66 | -- |
| Perspective Therapeutics Inc | 1.08m | -106.31m | 539.95m | 138.00 | -- | 1.45 | -- | 502.28 | -1.46 | -1.46 | 0.0147 | 3.26 | 0.0031 | -- | 5.43 | 7,789.86 | -31.00 | -- | -33.37 | -- | -- | -- | -9,889.68 | -- | -- | -- | 0.0067 | -- | 1.39 | -- | -109.13 | -- | -- | -- |
| Lexicon Pharmaceuticals Inc | 70.86m | -68.58m | 571.98m | 103.00 | -- | 3.96 | -- | 8.07 | -0.1894 | -0.1894 | 0.1954 | 0.3307 | 0.2689 | 1.06 | 27.10 | 688,000.00 | -26.02 | -55.75 | -29.23 | -66.32 | 99.41 | 95.36 | -96.77 | -1,103.37 | 5.63 | -6.58 | 0.3199 | -- | 2,481.48 | -37.35 | -13.15 | -- | 71.25 | -- |
| Contineum Therapeutics Inc | 0.00 | -59.39m | 575.34m | 41.00 | -- | 2.55 | -- | -- | -2.26 | -2.26 | 0.00 | 6.18 | 0.00 | -- | -- | 0.00 | -29.19 | -- | -30.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -285.99 | -- | -- | -- |
| Vor Biopharma Inc | 0.00 | -2.45bn | 576.71m | 159.00 | -- | -- | -- | -- | -386.85 | -386.85 | 0.00 | -246.54 | 0.00 | -- | -- | 0.00 | -1,676.47 | -49.21 | -1,891.22 | -52.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8052 | -- | -21.08 | -- |
| Design Therapeutics Inc | 0.00 | -67.45m | 582.74m | 55.00 | -- | 2.92 | -- | -- | -1.19 | -1.19 | 0.00 | 3.51 | 0.00 | -- | -- | 0.00 | -28.49 | -18.88 | -29.66 | -19.44 | -- | -- | -- | -98,925.22 | -- | -- | 0.00 | -- | -- | -- | 25.84 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to Perspective Therapeutics Inc's reporting currency: US Dollar USD
53.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Qatar Investment Authority Advisory (USA), Inc.as of 04 Feb 2026 | 7.07m | 9.52% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 5.77m | 7.77% |
| Farallon Capital Management LLCas of 31 Dec 2025 | 5.43m | 7.30% |
| FIAM LLCas of 30 Sep 2025 | 4.24m | 5.70% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 4.02m | 5.40% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.08m | 4.15% |
| Avidity Partners Management LPas of 30 Sep 2025 | 2.99m | 4.03% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 2.63m | 3.54% |
| Millennium Management LLCas of 30 Sep 2025 | 2.56m | 3.45% |
| Nicholson Wealth Management Group LLCas of 31 Dec 2025 | 1.62m | 2.18% |
More ▼
Data from 30 Sep 2025 - 04 Feb 2026Source: FactSet Research Systems Inc.
